| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 2mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Ganoderic acid B targets multiple pathways. It inhibits HIV-1 protease with an IC50 of 0.17 mM. It inhibits the activation of Epstein-Barr virus (EBV) antigens as a telomerase inhibitor. It is an inhibitor of cholesterol biosynthesis. It modulates NF-κB and PI3K/Akt signaling pathways. Its anti-hypertensive activity suggests effects on blood pressure regulation. It also has anti-inflammatory and anticancer activities.
|
|---|---|
| ln Vitro |
The levels of TNF-α, IL-6, and IL-1β in the serum of A549 cells stimulated by LPS are decreased by ganoderic acid B (0–40 μM, 1 h) [4].
In vitro, Ganoderic acid B inhibits HIV-1 protease with an IC50 value of 0.17 mM. It inhibits the activation of Epstein-Barr virus (EBV) antigens as a telomerase inhibitor. It is an inhibitor of cholesterol biosynthesis. It modulates NF-κB and PI3K/Akt signaling pathways. It has anti-hypertensive activity. These in vitro activities demonstrate its diverse pharmacological potential. |
| ln Vivo |
In animal models, ganoderic acid B (injected intraperitoneally at doses of 3 or 6 mg/kg) can shield the lungs of LPS sensors [4]. In a mouse experimental setting, ganoderic acid B (5 mg/kg, subcutaneous injection) protects the lungs induced by LPS [4].
In vivo activity data for Ganoderic acid B is limited in publicly available literature. As a compound with anti-HIV, anti-EBV, anti-hypertensive, and cholesterol-lowering activities in vitro, it is hypothesized to exhibit similar effects in animal models. However, specific in vivo efficacy studies, including pharmacokinetic and pharmacodynamic parameters, have not been detailed in the available sources. Further research is needed to fully characterize its in vivo activity and therapeutic potential. |
| Enzyme Assay |
For in vitro cell-free assays, the HIV-1 protease inhibitory activity of Ganoderic acid B can be measured using a standard protease assay. The compound is incubated with purified HIV-1 protease and a fluorogenic or chromogenic substrate. The IC50 value is calculated from a dose-response curve. Its telomerase inhibitory activity can be assessed using telomerase activity assays. Cholesterol biosynthesis inhibition can be studied using enzyme activity assays.
|
| Cell Assay |
For in vitro cellular assays, the effects of Ganoderic acid B on NF-κB and PI3K/Akt signaling can be assessed in cancer cell lines. Cells are treated with the compound, and signaling pathway activation is measured by Western blot using phospho-specific antibodies. Its anti-EBV activity can be assessed in EBV-infected cell lines by measuring viral antigen expression.
|
| Animal Protocol |
Animal/Disease Models: LPS-induced pneumonia in mice [4]
Doses: 3 or 6 mg/kg Route of Administration: intraperitoneal (ip) injection Experimental Results: Lung dry/wet weight (W/D) and lung myeloperoxidase activity were diminished. SOD increased, and MDA, TNF-α, IL-1β, and IL-6 levels diminished. For in vivo studies, Ganoderic acid B could be administered orally or intraperitoneally in animal models of HIV infection, cancer, hypertension, or hypercholesterolemia. Endpoints include viral load reduction, tumor volume measurement, blood pressure, and serum cholesterol levels. |
| ADME/Pharmacokinetics |
Ganoderic acid B (CAS 81907-61-1) has a molecular formula of C30H44O7 and a molecular weight of 516.67 g/mol. IUPAC name: Lanost-8-en-26-oic acid, 3,7-dihydroxy-11,15,23-trioxo-, (3β,7β,25R)-. Appearance: typically a powder. Solubility: DMSO and other organic solvents. Storage: typical for triterpenoids (desiccated, protected from light, -20°C). Purity: typically >98% for research use.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is publicly available. As a natural triterpenoid from Ganoderma lucidum, it is generally considered to have low toxicity, but standard toxicological studies would be required for drug development. In vitro cytotoxicity assays in various cell lines are typically performed alongside efficacy studies.
|
| References | |
| Additional Infomation |
Ganoderic acid B is a triterpenoid compound. It has been reported that ganoderic acid B exists in Ganoderma lucidum and Ganoderma sinense, and relevant data are available. See also: Ganoderma lucidum (partial).
Ganoderic acid B is a research-grade compound and is not approved for therapeutic use. It serves primarily as a pharmacological tool for studying HIV protease inhibition, telomerase inhibition, and cancer signaling pathways. Its mechanism of action involves inhibition of HIV-1 protease, telomerase inhibition, and modulation of NF-κB and PI3K/Akt pathways. It is a natural product from Ganoderma lucidum. No clinical trials have been reported. |
| Molecular Formula |
C30H44O7
|
|---|---|
| Molecular Weight |
516.6662
|
| Exact Mass |
516.308
|
| CAS # |
81907-61-1
|
| PubChem CID |
471003
|
| Appearance |
White to light brown solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
689.0±55.0 °C at 760 mmHg
|
| Flash Point |
384.4±28.0 °C
|
| Vapour Pressure |
0.0±4.9 mmHg at 25°C
|
| Index of Refraction |
1.565
|
| LogP |
2.33
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
37
|
| Complexity |
1070
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
C[C@H](CC(=O)C[C@@H](C)C(=O)O)[C@H]1CC(=O)[C@@]2([C@@]1(CC(=O)C3=C2[C@H](C[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O)C)O)C)C
|
| InChi Key |
LWPLEHFGBRFRKI-NBCWKOIPSA-N
|
| InChi Code |
InChI=1S/C30H44O7/c1-15(10-17(31)11-16(2)26(36)37)18-12-23(35)30(7)25-19(32)13-21-27(3,4)22(34)8-9-28(21,5)24(25)20(33)14-29(18,30)6/h15-16,18-19,21-22,32,34H,8-14H2,1-7H3,(H,36,37)/t15-,16-,18-,19+,21+,22+,28+,29-,30+/m1/s1
|
| Chemical Name |
(2R,6R)-6-[(3S,5R,7S,10S,13R,14R,17R)-3,7-dihydroxy-4,4,10,13,14-pentamethyl-11,15-dioxo-2,3,5,6,7,12,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methyl-4-oxoheptanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~96.77 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9355 mL | 9.6774 mL | 19.3547 mL | |
| 5 mM | 0.3871 mL | 1.9355 mL | 3.8709 mL | |
| 10 mM | 0.1935 mL | 0.9677 mL | 1.9355 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
